# Mesa Laboratories Inc: Form 10-Q for the period ended Sep 30, 2012

- Company: [Mesa Laboratories Inc](/companies/mlab.md) (CIK 724004)
- Form: 10-Q
- Filed: 2012-11-13
- Accepted by EDGAR: Nov 13, 2012, 10:56 ET
- Period: 2012-09-30
- Accession: 0001104659-12-077139
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724004/000110465912077139/a12-20175_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724004/000110465912077139/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2012-07-01 to 2012-09-30 | $4.5m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2012-04-01 to 2012-09-30 | $8.6m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2012-07-01 to 2012-09-30 | $7.2m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2012-04-01 to 2012-09-30 | $13.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2012-07-01 to 2012-09-30 | $519.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2012-04-01 to 2012-09-30 | $899.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2012-07-01 to 2012-09-30 | $3.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2012-04-01 to 2012-09-30 | $6.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2012-07-01 to 2012-09-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2012-04-01 to 2012-09-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-07-01 to 2012-09-30 | $2.2m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months, 2012-04-01 to 2012-09-30 | $4.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.64 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2012-04-01 to 2012-09-30 | $1.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2012-04-01 to 2012-09-30 | $1.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-07-01 to 2012-09-30 | 3,538,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2012-04-01 to 2012-09-30 | 3,531,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2012-04-01 to 2012-09-30 | $4.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Dividends paid | 6 months, 2012-04-01 to 2012-09-30 | $871.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2012-04-01 to 2012-09-30 | $57.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-09-30 | $2.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-30 | $16.8m | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-30 | $64.4m | us-gaap:Assets |
| Current liabilities | at 2012-09-30 | $3.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-09-30 | $16.0m | us-gaap:Liabilities |
| Long-term debt | at 2012-09-30 | $8.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2012-09-30 | $48.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 17,156 characters.

### Forward Looking Statements

*This report contains information that may constitute “forward-looking statements.” Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Part II, “Item 1A. Risk Factors” and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2012, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.*

### General Discussion

Mesa Laboratories, Inc. has two divisions — Our Instruments division manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries. Our Biological Indicators division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes in the hospital, dental, medical device and pharmaceutical industries. We follow a philosophy of manufacturing a high quality product and providing a high level of on-going service for those products.

Our revenues come from two main sources — products sales, and parts and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Parts and service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we try to pass along cost increases in order to maintain our margins. As part of the integration of our previous biological indicator acquisitions we have been adjusting prices to achieve price parity for similar products.

Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however differences in gross margins between different product lines, and ultimately the mix of sales between different segments may continue to impact our overall gross margin.

Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, they may vary with sales levels. Labor costs and amortization of intangible assets drive 70-80% of general and administrative expense. Research and development expense is predominantly comprised of labor costs.

In May 2012, we completed the Bios Acquisition by acquiring specific assets and assuming certain liabilities of Bios, a New Jersey corporation. The purchase price for the acquired net assets was $16,660,000 and potential contingent consideration based on revenue growth over a three year earn-out period. The contingent consideration arrangement requires us to pay Bios if cumulative revenues related to the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential undiscounted future payment that we could be required to make ranges from $0 to $6,710,000. We borrowed $11,000,000 under our Line of Credit to finance the acquisition, with the balance being paid from available cash.

Our New Jersey operations were not significantly impacted by Hurricane Sandy.

### Results of Operations

The following table sets forth, for the periods indicated, condensed statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):

|  | Three months ended September 30, 2012 | 2011 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $11,706 | $9,701 | $2,005 | 21% |
| Cost of revenues | 4,458 | 3,927 | 531 | 14% |
| Gross profit | 7,248 | 5,774 | 1,474 | 26% |
| Gross margin | 62% | 60% | 2% |  |
| Operating expenses | 3,760 | 2,488 | 1,272 | 51% |
| Net income | 2,248 | 2,053 | 195 | 9% |
| Net profit margin | 19% | 21% | (2)% |  |

*(Dollars in thousands)*

|  | Six months ended September 30, 2012 | 2011 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $22,266 | $18,998 | $3,268 | 17% |
| Cost of revenues | 8,562 | 7,836 | 726 | 9% |
| Gross profit | 13,704 | 11,162 | 2,542 | 23% |
| Gross margin | 62% | 59% | 3% |  |
| Operating expenses | 6,996 | 5,183 | 1,813 | 35% |
| Net income | 4,348 | 3,733 | 615 | 16% |
| Net profit margin | 20% | 20% | 0% |  |

### Revenues

The following table summarizes our revenues by source (in thousands, except percent data):

|  | Three months ended September 30, 2012 | 2011 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators – Product | $5,320 | $5,190 | $130 | 3% |
| Instruments: |  |  |  |  |
| Product | 4,474 | 2,780 | 1,694 | 61% |
| Parts and disposables | 736 | 804 | (68) | (8)% |
| Service | 1,176 | 927 | 249 | 27% |
| Total Instruments | 6,386 | 4,511 | 1,875 | 42% |
|  | $11,706 | $9,701 | 2,005 | 21% |

|  | Six months ended September 30, 2012 | 2011 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Biological Indicators – Product | $10,438 | $9,859 | $579 | 6% |
| Instruments: |  |  |  |  |
| Product | 8,083 | 5,778 | 2,305 | 40% |
| Parts and disposables | 1,492 | 1,502 | (10) | (1)% |
| Service | 2,253 | 1,859 | 394 | 21% |
| Total Instruments | 11,828 | 9,139 | 2,689 | 29% |
|  | $22,266 | $18,998 | 3,268 | 17% |

14

Instruments revenues increased for the three and six months ended September 30, 2012 primarily due to the Bios Acquisition in May 2012. Biological indicator product sales and other Instruments revenues showed modest growth due to continued organic growth, achieved through existing customers and expansion into new markets.

### Cost of Revenues / Gross Profit

Biological indicator gross profit increased approximately $150,000 and $740,000, respectively, for the three and six months ended September 30, 2012, compared to the prior year, due to improved manufacturing efficiencies and higher sales.

Gross profit for Instruments increased approximately $1,320,000 and $1,800,000, respectively, for the three and six months ended September 30, 2012, compared to the prior year, primarily due to the Bios Acquisition. Gross profit for other Instruments product lines was relatively unchanged.

### Operating Expenses

Selling expenses increased approximately $34,000 and $97,000, respectively, for the three and six months ended September 30, 2012, compared to the prior year. The Bios Acquisition resulted in an increase of our selling costs which was primarily offset with cost savings elsewhere. As a percent of revenues, selling expense remained relatively flat.

General and administrative expense increased approximately $1,025,000 and $1,531,000, respectively, for the three and six months ended September 30, 2012, compared to the prior year. The increases relate primarily to a) additional amortization of approximately $290,000 and $490,000, respectively, from the Bios Acquisition and the amortization of trademarks, which started in the fourth quarter of our year ending March 31, 2012; b) general administrative expenses from the Bios Acquisition; c) increased labor costs for additional personnel and salary adjustments, d) professional fees of approximately $80,000 and $150,000, respectively, associated with the Bios Acquisition; and e) consulting fees of approximately $110,000 and $140,000, respectively, related to upgrading our ERP system and implementing system-oriented controls as part of our Sarbanes-Oxley compliance efforts.

Research and development expense increased approximately $213,000 and $185,000, respectively, for the three and six months ended September 30, 2012, compared to the prior year. The increases are due to additional internal personnel added as a result of the Bios Acquisition and external R&D consulting. We continue our commitment to research and development, however, the cost of intangible assets that are purchased from others for use in research and development activities and have alternative future uses are capitalized and amortized over their expected useful life. During the year ended March 31, 2012, we funded certain Biological Indicator research which was capitalized as an intangible asset as it had alternative future uses. That project is ongoing during our year ending March 31, 2013.

### Net Income

Net income varied consistently with the growth in revenues and gross profit, as we managed our other expenses. Our effective income tax rate decreased period over period because the goodwill associated with the Bios Acquisition is deductible for tax purposes.

### Liquidity and Capital Resources

Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to shareholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions.

We invest surplus cash in various interest bearing instruments, including money market funds. All investments are fixed dollar investments with variable rates in order to minimize the risk of principal loss.

Working capital is the amount by which current assets exceed current liabilities. We had working capital of approximately $13,371,000 and $14,899,000, respectively, at September 30 and March 31, 2012. The decrease in working capital is due to the use of cash for the Bios Acquisition and repayment of long-term debt, partially offset by higher revenues and net income which generated increased cash flow.

In February 2012, we entered into the Credit Facility, which is comprised of a three year agreement for a $20,000,000 revolving line of credit and up to $1,000,000 of letters of credit. Funds from the Credit Facility may be used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures. In February 2012, we also extinguished our obligations under our previous debt agreement. In May 2012, we borrowed $11,000,000 against the Line of Credit to partially finance the Bios Acquisition. At September 30, 2012, we had unused capacity under our Line of Credit of $12,000,000. In October 2012 we made an additional principal payment of $1,500,000.

On October 1, 2012, we amended our articles of incorporation to increase the number of authorized shares of common stock from 8 million to 25 million.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.

On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 156,412 shares of common stock under this program from inception through September 30, 2012.

On November 12, 2003, our Board of Directors instituted a policy of paying regular quarterly dividends. Dividends per share paid by quarter were as follows:

|  | Year ending March 31, 2013 | 2012 |
| --- | ---: | ---: |
| First quarter | $0.13 | $0.12 |
| Second quarter | 0.13 | 0.12 |
| Third quarter | — | 0.13 |
| Fourth quarter | — | 0.13 |

In November, 2012, our Board of Directors declared a quarterly cash dividend of $0.14 per share of common stock, payable on December 14, 2012, to shareholders of record at the close of business on November 30, 2012.

### Cash Flows

Our cash flows from operating, investing and financing activities were as follows (in thousands):

|  | Six months ended September 30, 2012 | 2011 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $4,926 | $4,605 |
| Net cash used in investing activities | (17,030) | (343) |
| Net cash provided by (used in) financing activities | 7,685 | (2,856) |

Net cash provided by operating activities changed primarily due to increased revenues and improved net income, as well as management of working capital.

Net cash used in investing activities was driven by a $16,660,000 acquisition in May 2012. Purchases of property, plant and equipment were $370,000 and $343,000, respectively, for the six months ended September 30, 2012 and 2011.

Financing activity for the six months ended September 30, 2012, included borrowing under our Line of Credit of $11,000,000, proceeds from the exercise of stock options of $613,000, partially offset by payments on long-term debt of $3,000,000 and the payment of dividends of $871,000. Activity for the six months ended September 30, 2011, included repayment of debt of $2,500,000, payment of dividends of $788,000, partially offset by proceeds from the exercise of stock options of $512,000.

At September 30, 2012, we had contractual obligations for open purchase orders for routine purchases of supplies and inventory, which would be payable in less than one year. In September 2011, we entered into a license agreement for certain biological indicator technology and up to $225,000 of additional payments may be made in the future, depending on meeting certain development and performance milestones. As part of our Bios Acquisition, the Bios Agreement includes a provision for contingent consideration based on revenue growth over a three year earn-out period. The contingent consideration arrangement requires us to pay Bios if cumulative revenues from the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential undiscounted future payment that we could be required to make ranges from $0 to $6,710,000.

### Critical Accounting Estimates

Our condensed financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2012 in the Critical Accounting Policies and Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

## Market risk

As filed, 318 characters.

We are exposed to a variety of market risks, currently all investments are in dollar denominated accounts, such as money market funds, with variable interest rates. In the normal course of business, we employ established policies and procedures to manage our exposure to changes in the market value of our investments.

## Controls and procedures

As filed, 2,990 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of September 30, 2012. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at September 30, 2012.

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as required by Sarbanes-Oxley (SOX) Section 404(a). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of September 30, 2012. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at September 30, 2012. As allowed, this evaluation excludes the operations of Bios due to the recency of the acquisition. Revenues related to the Bios Acquisition were approximately 11% of total revenues for the six month period ended September 30, 2012.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2012, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,736 characters.

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our annual report on Form 10-K for the year ended March 31, 2012, under the heading “Part I — Item 1A. Risk Factors.” There has been no material change in those risk factors other than the following:

### Global economic conditions could materially adversely affect the Company

Our operations and performance depend on worldwide economic conditions. Uncertainty about global economic conditions poses a risk as businesses postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Other factors that could influence demand include increases in fuel and other energy costs, conditions in the real estate, labor and healthcare costs, access to credit and other macroeconomic factors affecting spending behavior. These worldwide and regional economic conditions could have a material adverse effect on demand for our products and services as our customers reduce or delay capital equipment and other types of purchases.

In the event of financial turmoil affecting the banking system and financial markets, additional consolidation of the financial services industry, or significant financial service institution failures, there could be a new or incremental tightening in the credit markets, low liquidity, and extreme volatility in fixed income, credit, currency, and equity markets. This could have a number of effects on our business, including the insolvency or financial instability of our customers.

Filed Nov 13, 2012.
Source: SEC EDGAR, the filing index for accession 0001104659-12-077139. Last ingested by Listed: Nov 13, 2026, 07:45 ET. No prices; not investment advice.
